Some information on this page may be available only to Healthcare Professionals. Please

About

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. To learn more about Novartis in Singapore, visit https://www.novartis.com.sg

Website: https://www.novartis.com.sg/

Facebook: https://www.facebook.com/novartis

Twitter: https://twitter.com/novartis

Youtube: https://www.youtube.com/channel/UCrOUkNI1eCMumFJ1PK6PaYw

Instagram: http://instagram.com/novartis

LinkedIn: https://www.linkedin.com/company/novartis-sg/

Media

Videos

Branches

1

Novartis

20 Pasir Panjang Road #10-25/28, Mapletree Business City (West Tower), Singapore 117439

Key Trials

6 trials shown

Novartis

Novartis

Key trial

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

24 February 2021

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose.

Trial number:
NCT04699188
Study type:
Targeted therapy, Biomarker
Trial phase:
1, 2
Overall status:
Recruiting
Novartis

Novartis

Key trial

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

7 September 2020

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

Trial number:
NCT04240704
Study type:
Chemotherapy, Targeted therapy
Trial phase:
1
Overall status:
Recruiting
Novartis

Novartis

Key trial

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

18 July 2018

The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Trial number:
NCT03549000
Study type:
Immunotherapy
Trial phase:
1
Overall status:
Recruiting
Novartis

Novartis

Key trial

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

28 August 2017

The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.

Trial number:
NCT03207867
Study type:
Immunotherapy
Trial phase:
2
Overall status:
Recruiting
Novartis

Novartis

Key trial

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

26 May 2017

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Trial number:
NCT03114319
Study type:
Targeted therapy, Biomarker
Trial phase:
1
Overall status:
Recruiting
Novartis

Novartis

Key trial

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

11 December 2015

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Trial number:
NCT02584933
Study type:
Targeted therapy
Trial phase:
4
Overall status:
Recruiting